Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Population Health Research Institute
Bristol-Myers Squibb
Information provided by (Responsible Party):
Jeff Healey, Population Health Research Institute Identifier:
First received: September 4, 2013
Last updated: October 5, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2019
  Estimated Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)